Evidence map›Paper›PMID 34387808›Full record

ArticleInvestigational new drugs2021

IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.

Yuefeng Hu, Dong Liu, Peilin Cui, Wen Zhang, Hao Chen, Chunmei Piao, Yongcheng Lu, Xuesong Liu, Yue Wang, Jingwei Liu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Yuefeng Hu *Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Dong Liu *Department of Radiology, The First Hospital of Tsinghua University, Beijing, China.
Peilin Cui *Department of Internal Medicine, Beijing Tiantan Hospital, Capital Medical University, Bejing, China.
Wen ZhangDepartment of Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hao ChenDepartment of Surgical Oncology, Lanzhou University Second Hospital, Lanzhou, China.
Chunmei PiaoDepartment of Oncology, Institute of Heart Lung and Blood Vessel Diseases, Beijing Anzhen Hospital Affiliated to the Capital Medical University, Beijing, China.
Yongcheng LuDepartment of Physiology, Michigan State University, East Lansing, MI, USA.
Xuesong LiuDepartment of Oncology, Beijing Biohealthcare Biotechnology Co, Ltd, Beijing, China.
Yue WangDepartment of Oncology, Beijing Biohealthcare Biotechnology Co, Ltd, Beijing, China.
Jingwei LiuDepartment of Oncology, Beijing Biohealthcare Biotechnology Co, Ltd, Beijing, China. liujw@biohealthcare.com.cn.ORCID 0000-0003-4943-3926
Xu LuDepartment of Oncology, Beijing Biohealthcare Biotechnology Co, Ltd, Beijing, China.
Capital Medical University · CNBeijing Biocytogen (China) · CNBeijing Hua Xin Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNLanzhou University Second Hospital · CNMichigan State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives To test the antitumor potential of lymphocytes transferred via adoptive cell therapy (ACT) in a mouse model of human gastric cancer (GC), and to evaluate the clinical efficacy and safety of combining lymphocytes as adjuvant therapy with first-line chemotherapy in patients with GC. Methods We constructed a human GC xenograft model in sublethally irradiated 6-8-week-old male NCG mice. MKN-45 cells (1 × 10

Indexed as

AdultAgedAnimalsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleHumansImmunotherapy, AdoptiveInterleukin-15LymphocytesMaleMiceMiddle AgedNeoplasm StagingOxaliplatinStomach NeoplasmsInterleukin-15OxaliplatinAdoptive transferAllogenic T lymphocyteCancer immunotherapyGastric cancerXenograft model

Identifiers

PMID34387808
OpenAlexW3156842524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.